{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:04:48Z","timestamp":1767035088077,"version":"3.37.3"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Psoriasis (PsO) is an immune-mediated chronic inflammatory disease that results in severe outcomes that impact the patient\u2019s quality of life and work productivity. We investigated the effectiveness of secukinumab in patients with chronic plaque psoriasis and psoriatic arthritis (PsA) over a 12-month period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a longitudinal, retrospective study of the medical records of 81 patients with psoriasis and\/or psoriatic arthritis who had been treated with secukinumab for at least 12 weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The Psoriasis Area Severity Index (PASI), Body Surface Area (BSA) percentage, and Dermatology Quality of Life Index (DLQI) among patients with PsO and PsO-PsA showed a statistically significant decrease from baseline over 12 months by approximately 9.86, 19.3%, and 9.7, respectively (<jats:italic>p<\/jats:italic> values\u2009&lt;\u20090.001 for each). Moreover, there was a statistically significant decrease in the overall Disease Activity in Psoriatic Arthritis score (DAPSA) by approximately 22.35 from baseline over 12 months of treatment (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Considering the patients who started secukinumab 12 months or more prior to the study cutoff date, the 12-month retention rate was 85%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In a Saudi real-world setting, secukinumab proved to be an efficient medication with high efficacy and retention rates.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42358-024-00371-1","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T17:01:51Z","timestamp":1714410111000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of secukinumab in patients with  psoriasis and psoriatic arthritis in a Saudi real-world setting"],"prefix":"10.1186","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-6938","authenticated-orcid":false,"given":"Ibrahim A.","family":"Al-Homood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5497-0458","authenticated-orcid":false,"given":"Mohammed","family":"Alajlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8149-8944","authenticated-orcid":false,"given":"Majid","family":"Alberdisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5072-3722","authenticated-orcid":false,"given":"Mohammad","family":"Alturki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-8232","authenticated-orcid":false,"given":"Ahmed Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9378-740X","authenticated-orcid":false,"given":"Nancy","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,29]]},"reference":[{"issue":"3","key":"371_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014 Mar;70(3):512\u201316. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213012681.","journal-title":"J Am Acad Dermatol"},{"key":"371_CR2","volume-title":"Pharmacotherapy: a pathophysiologic approach, 10e","author":"RM Law","year":"2017","unstructured":"Law RM, Gulliver WP. Psoriasis. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, editors. Pharmacotherapy: a pathophysiologic approach, 10e. New York, NY: McGraw-Hill Education; 2017. Available from: http:\/\/accesspharmacy.mhmedical.com\/content.aspx?aid=1153075009."},{"issue":"2","key":"371_CR3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DPM, Griffiths CEM, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377\u201385. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202%D71536098X.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"371_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5144\/0256-4947.2019.22","volume":"39","author":"HM Alshamrani","year":"2019","unstructured":"Alshamrani HM, Alsolami MA, Alshehri AM, Salman AK, Alharbi MW, Alzuhayri AJ, et al. Pattern of skin diseases in a university hospital in Jeddah, Saudi Arabia: age and sex distribution. Ann Saudi Med. 2019 Jan;39(1):22\u201328. Available from: http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2019.22.","journal-title":"Ann Saudi Med"},{"issue":"4","key":"371_CR5","first-page":"507","volume":"25","author":"HH Shelleh","year":"2004","unstructured":"Shelleh HH, Al-Hatiti HS. Pattern of skin diseases in a hospital in southwestern Saudi Arabia. Saudi Med J. 2004 Apr;25(4):507\u201310. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15083226.","journal-title":"Saudi Med J"},{"issue":"1","key":"371_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5144\/0256-4947.1997.112","volume":"17","author":"PK Agarwal","year":"1997","unstructured":"Agarwal PK. Pattern of skin diseases in Al-Jouf region. Ann Saudi Med. 1997 Jan;17(1):112\u201314. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17377479.","journal-title":"Ann Saudi Med"},{"key":"371_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2147\/CCID.S352654","volume":"15","author":"F Alzeer","year":"2022","unstructured":"Alzeer F, AlOtair H, Aleisa A. Epidemiology and cutaneous manifestations of psoriasis in Saudi Arabia: a narrative review. Clin Cosmet Investig Dermatol. 2022 Feb;15:347\u201355. Available from: https:\/\/www.dovepress.com\/epidemiology-and-cutaneous-manifestations-of-psoriasis-in-saudi-arabia-peer-reviewed-fulltext-article-CCID.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"371_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40744-019-0159-1","volume":"6","author":"J Belasco","year":"2019","unstructured":"Belasco J, Wei N. Psoriatic arthritis: what is happening at the joint? Rheumatol Ther. 2019 Sep;6(3):305\u201315. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31102105.","journal-title":"Rheumatol Ther"},{"issue":"Suppl 2","key":"371_CR9","first-page":"ii14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005 Mar;64(Suppl 2):ii14\u20137. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15708927.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"371_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.31128\/AJGP-08-19-5035","volume":"49","author":"BS Daniel","year":"2020","unstructured":"Daniel BS. The multiple comorbidities of psoriasis: the importance of a holistic approach. Aust J Gen Pract. 2020 Jul;49(7):433\u201337. Available from: https:\/\/www1.racgp.org.au\/ajgp\/2020\/july\/the-multiple-comorbidities-of-psoriasis.","journal-title":"Aust J Gen Pract"},{"issue":"1","key":"371_CR11","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","volume":"80","author":"F Alinaghi","year":"2019","unstructured":"Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251\u2013265.e19. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29928910.","journal-title":"J Am Acad Dermatol"},{"key":"371_CR12","first-page":"213","volume":"12","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Bellinato F, Maurelli M, Geat D, Zabotti A, McGonagle D, et al. Reducing the risk of developing psoriatic arthritis in patients with psoriasis. Psoriasis (Auckland NZ). 2022;12:213\u201320. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35975124.","journal-title":"Psoriasis (Auckland NZ)"},{"issue":"8","key":"371_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00296-019-04319-3","volume":"39","author":"M Bedaiwi","year":"2019","unstructured":"Bedaiwi M, Al-Homood IA, El-Garf A, Uthman I, Sunna N, Nassier R, et al. Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East. Rheumatol Int. 2019 Aug;39(8):1321\u201329. Available from: http:\/\/link.springer.com\/10.1007\/s00296-019-04319-3.","journal-title":"Rheumatol Int"},{"issue":"3","key":"371_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018 Dec;55(3):379\u201390. Available from: http:\/\/link.springer.com\/10.1007\/s12016-018-8702-3.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9","key":"371_CR15","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019 Sep;78(9):1167\u201378. Available from: http:\/\/ard.bmj.com\/content\/78\/9\/1167.abstract.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"371_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/14712598.2018.1481503","volume":"18","author":"M Galluzzo","year":"2018","unstructured":"Galluzzo M, Talamonti M, De Simone C, D\u2019Adamio S, Moretta G, Tambone S, et al. Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opin Biol Ther. 2018 Jul;18(7):727\u201335. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2018.1481503.","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"371_CR17","doi-asserted-by":"publisher","first-page":"272","DOI":"10.5152\/eurjrheum.2017.17037","volume":"4","author":"EA Wang","year":"2017","unstructured":"Wang EA, Suzuki E, Maverakis E, Adamopoulos IE. Targeting IL-17 in psoriatic arthritis. Eur J Rheumatol. 2017 Dec;4(4):272\u201377. Available from: https:\/\/eurjrheumatol.org\/\/en\/targeting-il-17-in-psoriatic-arthritis-133030.","journal-title":"Eur J Rheumatol"},{"issue":"5","key":"371_CR18","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. 2021 May;80(5):582\u201390. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33334727.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"371_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40265-015-0359-0","volume":"75","author":"M Sanford","year":"2015","unstructured":"Sanford M, McKeage K. Secukinumab: first global approval. Drugs. 2015 Feb;75(3):329\u201338. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25648267.","journal-title":"Drugs"},{"issue":"9","key":"371_CR20","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1111\/jdv.14878","volume":"32","author":"R Bissonnette","year":"2018","unstructured":"Bissonnette R, Luger T, Tha\u00e7i D, Toth D, Lacombe A, Xia S, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1507\u201314. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29444376.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"371_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/acr.23111","volume":"69","author":"A Kavanaugh","year":"2017","unstructured":"Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, et al. Secukinumab for long-term treatment of psoriatic arthritis: a two-year followup from a phase III, randomized, double-blind placebo-controlled study. Arthritis Care Res (Hoboken). 2017 Mar;69(3):347\u201355. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acr.23111.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"371_CR22","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/acr.23537","volume":"70","author":"LC Coates","year":"2018","unstructured":"Coates LC, Mease PJ, Gossec L, Kirkham B, Sherif B, Gaillez C, et al. Minimal disease activity among active psoriatic Arthritis patients treated with secukinumab: 2-year results from a multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529\u201335. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acr.23537.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"371_CR23","doi-asserted-by":"publisher","first-page":"e001519","DOI":"10.1136\/rmdopen-2020-001519","volume":"7","author":"R Ramonda","year":"2021","unstructured":"Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A, et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021 Feb;7(1):e001519. Available from: https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001519.","journal-title":"RMD Open"},{"issue":"3","key":"371_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","volume":"73","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Blauvelt A, Reich K, Tsai T-F, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015 Sep;73(3):400\u201309. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26092291.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"371_CR25","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CEM, Papp K, et al. Secukinumab in plaque psoriasis\u2013results of two phase 3 trials. N Engl J Med. 2014 Jul;371(4):326\u201338. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25007392.","journal-title":"N Engl J Med"},{"issue":"1","key":"371_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Reich K, Tsai T-F, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study. J Am Acad Dermatol. 2017 Jan;76(1):60\u201369.e9. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27663079.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"371_CR27","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/09546634.2016.1255306","volume":"28","author":"NJ Korman","year":"2017","unstructured":"Korman NJ, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, et al. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis. J Dermatolog Treat. 2017 Aug;28(5):384\u201389. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27832717.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"371_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/ijd.13236","volume":"55","author":"B Strober","year":"2016","unstructured":"Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. Int J Dermatol. 2016 Apr;55(4):401\u201307. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26866518.","journal-title":"Int J Dermatol"},{"doi-asserted-by":"crossref","unstructured":"Mease PJ, Landew\u00e9 R, Rahman P, Tahir H, Singhal A, Boettcher E, et al. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021 Jul;7(2). Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34330846.","key":"371_CR29","DOI":"10.1136\/rmdopen-2021-001600"},{"issue":"4","key":"371_CR30","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.3390\/ijerph20043767","volume":"20","author":"MA Albanghali","year":"2023","unstructured":"Albanghali MA. Prevalence of consanguineous marriage among Saudi Citizens of Albaha, a cross-sectional study. Int J Environ Res Public Health. 2023 Feb;20(4):3767. Available from: https:\/\/www.mdpi.com\/1660-4601\/20\/4\/3767.","journal-title":"Int J Environ Res Public Health"},{"issue":"7","key":"371_CR31","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1007\/s10067-018-4090-6","volume":"37","author":"M Megna","year":"2018","unstructured":"Megna M, Balato A, Napolitano M, Gallo L, Caso F, Costa L, et al. Psoriatic disease treatment nowadays: unmet needs among the \u201cjungle of biologic drugs and small molecules\u201d. Clin Rheumatol. 2018 Jul;37(7):1739\u201341. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29644570.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"371_CR32","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.abd.2021.11.002","volume":"97","author":"I Oguz Topal","year":"2022","unstructured":"Oguz Topal I, Baysak S, Altunay \u0130K, Kara Polat A, Ar\u0131kan EE, \u00d6zkur E, et al. Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study. An Bras Dermatol. 2022;97(5):566\u201374. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35843765.","journal-title":"An Bras Dermatol"},{"issue":"2","key":"371_CR33","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/14712598.2020.1708897","volume":"20","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, D\u2019Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opin Biol Ther. 2020 Feb;20(2):173\u201382. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2020.1708897.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"371_CR34","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1080\/09546634.2019.1656797","volume":"32","author":"AS Van Voorhees","year":"2021","unstructured":"Van Voorhees AS, Mason MA, Harrold LR, Guo N, Guana A, Tian H, et al. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. J Dermatolog Treat. 2021 May;32(3):302\u201309. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31581919.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"371_CR35","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s13555-021-00675-w","volume":"12","author":"P Foley","year":"2022","unstructured":"Foley P, Tsai T-F, Rodins K, Hamadah IR, Ammoury A, Dayem HA, et al. Effectiveness and safety of secukinumab for psoriasis in a real-world clinical Setting in the Asia-Pacific and Middle East regions: results from the REALIA study. Dermatol Ther (Heidelb). 2022 Feb;12(2):511\u201327. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35038128.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"371_CR36","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1080\/09546634.2022.2116266","volume":"33","author":"B Strober","year":"2022","unstructured":"Strober B, Patil D, McLean RR, Moore-Clingenpeel M, Guo N, Levi E, et al. Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting. J Dermatolog Treat. 2022 Nov;33(8):3178\u201387. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2022.2116266.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"371_CR37","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s13555-022-00849-0","volume":"13","author":"KA Papp","year":"2023","unstructured":"Papp KA, Gooderham M, Dei-Cas I, LopezTello A, Garcia-Rodriguez JC, Taveras CY, et al. Effectiveness and safety of secukinumab in Latin American patients with moderate to severe plaque psoriasis: PURE registry 12-month data. Dermatol Ther (Heidelb). 2023 Jan;13(1):269\u201383. Available from: https:\/\/link.springer.com\/10.1007\/s13555-022-00849-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"7","key":"371_CR38","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/acr.24560","volume":"74","author":"B Michelsen","year":"2022","unstructured":"Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, et al. Real-world six- and twelve-month drug retention, remission, and response rates of secukinumab in 2,017 patients with psoriatic arthritis in thirteen European countries. Arthritis Care Res (Hoboken). 2022 Jul;74(7):1205\u201318. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acr.24560.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"371_CR39","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3389\/fmed.2020.00288","volume":"7","author":"K Klavdianou","year":"2020","unstructured":"Klavdianou K, Lazarini A, Grivas A, Tseronis D, Tsalapaki C, Rapsomaniki P, et al. Real life efficacy and safety of secukinumab in biologic-experienced patients with psoriatic arthritis. Front Med. 2020;7:288. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32637422.","journal-title":"Front Med"},{"issue":"5","key":"371_CR40","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3899\/jrheum.220823","volume":"50","author":"DD Gladman","year":"2023","unstructured":"Gladman DD, Choquette D, Khraishi M, Inman RD, Hussein S, Neish D, et al. Real-world retention and clinical effectiveness of secukinumab for psoriatic arthritis: results from the Canadian spondyloarthritis research network. J Rheumatol. 2023 May;50(5):641\u201348. Available from: http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220823.","journal-title":"J Rheumatol"},{"issue":"1","key":"371_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s42358-023-00295-2","volume":"63","author":"F Molica Colella","year":"2023","unstructured":"Molica Colella F, Zizzo G, Parrino V, Filosa MT, Cavaliere R, Fazio F, et al. Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort. Adv Rheumatol. 2023 Mar;63(1):15. Available from: https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-023-00295-2.","journal-title":"Adv Rheumatol"},{"issue":"4","key":"371_CR42","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40744-022-00460-x","volume":"9","author":"U Kiltz","year":"2022","unstructured":"Kiltz U, Sfikakis PP, Gaffney K, Bounas A, Gullick N, Lespessailles E, et al. Interim 2-year analysis from SERENA: a real-world study in patients with psoriatic arthritis or ankylosing spondylitis treated with secukinumab. Rheumatol Ther. 2022 Aug;9(4):1129\u201342. Available from: https:\/\/link.springer.com\/10.1007\/s40744-022-00460-x.","journal-title":"Rheumatol Ther"},{"issue":"10","key":"371_CR43","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1111\/jdv.18329","volume":"36","author":"M Augustin","year":"2022","unstructured":"Augustin M, Sator PG, von Kiedrowski R, Conrad C, Rigopoulos D, Romanelli M, et al. Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study. J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1796\u2013804. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35696305.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"371_CR44","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.1016\/j.jaad.2016.05.049","volume":"75","author":"YYM Huang","year":"2016","unstructured":"Huang YYM, Ruth JS, Hsu S. Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks. J Am Acad Dermatol. 2016 Oct;75(4):e169. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27646769.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"371_CR45","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1111\/jdv.14468","volume":"32","author":"JR Georgakopoulos","year":"2018","unstructured":"Georgakopoulos JR, Ighani A, Zhou LL, Yeung J. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e32\u20134. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28695989.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"371_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1080\/09546634.2018.1528000","volume":"30","author":"J Notario","year":"2019","unstructured":"Notario J, Deza G, Vilarrasa E, Valent\u00ed F, Mu\u00f1oz C, Mollet J, et al. Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. J Dermatolog Treat. 2019 Jul;30(5):424\u201329. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2018.1528000.","journal-title":"J Dermatolog Treat"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00371-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-024-00371-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-024-00371-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T17:03:32Z","timestamp":1720026212000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-024-00371-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["371"],"URL":"https:\/\/doi.org\/10.1186\/s42358-024-00371-1","relation":{},"ISSN":["2523-3106"],"issn-type":[{"type":"electronic","value":"2523-3106"}],"subject":[],"published":{"date-parts":[[2024,4,29]]},"assertion":[{"value":"15 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the protocol, the Guidelines for Good Pharmacoepidemiology Practices (GPP) of the International Society for Pharmacoepidemiology (ISPE 2008), the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines, and the ethical principles laid down in the Declaration of Helsinki. All study data were accessed in accordance with ethics and research governance requirements. No patient identifiers were collected to ensure the complete protection of patients\u2019 privacy. The study was approved by the local institutional review board (IRB) at King Abdulaziz City for Science and Technology (KACST) with registration number <b>H-01-R-012<\/b>. Additionally, the IRB registration number with OHRP\/NIH, USA is <b>IRB00010471<\/b>, while the approval number Federal Wide Assurance NIH, USA is <b>FWA00018774<\/b>.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NZ, AA and MA are employees of the company Novartis Pharmaceuticals. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. IA is an employee of KFMC, has received grant\/research support from Novartis, GSK and Pfizer and speaker honoraria from Pfizer, AbbVie, GSK, Novartis, Eli Lilly.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}